Intra-QT Spectral Coherence as a Possible Noninvasive Marker of Sustained Ventricular Tachycardia

Table 1

General characteristics in the two study groups.

Variables	VT group; 𝑁: 27	No-VT; 𝑁: 97	𝑃 values
Age, yrs	64.3 ± 11.3	59.4 ± 12.4	ns
M/F,	25/2	86/11	ns
BMI, kg/m^2	25.4 ± 2.4	26.5 ± 3.3	ns
HR, beats/min	64 ± 9.5	63 ± 8.4	ns
SBP, mm Hg	123 ± 25	124 ± 23	ns
DBP, mm Hg	65 ± 10	67 ± 9	ns
EF, %	41 ± 10	38 ± 11	ns
QT𝑒Bazett, ms	401 ± 57	388 ± 60	ns
QT𝑒Fridericia, ms	398 ± 55	385 ± 63	ns
QT𝑒Lilly, ms	399 ± 56	386 ± 62	ns
QT𝑒Framingham, ms	398 ± 56	386 ± 62	ns
QT𝑝Bazett, ms	312 ± 51	299 ± 44	ns
QT𝑝Fridericia, ms	309 ± 49	297 ± 45	ns
QT𝑝Lilly, ms	310 ± 50	297 ± 44	ns
QT𝑝Framingham, ms	309 ± 50	298 ± 42	ns
𝑇𝑒Bazett, ms	89 ± 24	92 ± 37	ns
𝑇𝑒Fridericia, ms	89 ± 24	92 ± 37	ns
𝑇𝑒Lilly, ms	89 ± 24	92 ± 37	ns
𝑇𝑒Framingham, ms	93 ± 28	96 ± 62	ns
LVEF, %	41 ± 10	38 ± 11	ns
NYHA class, II/II	10/17	41/56	ns
𝛽-Blockers, 𝑛	20 (74%)	76 (78%)	ns
Furosemide	10 (37%)	51 (53%)	ns
ACEi/sartans	21 (78%)	80 (82%)	ns
Spironolactone	10 (37%)	32 (33%)	ns
Amiodarone	7 (26%)	19 (20%)	ns
Ivabradine	2 (7%)	9 (9%)	ns
Digoxin	3 (11%)	11 (11%)	Ns

Data are expressed as mean ± SD. VT: sustained ventricular tachycardia; M/F: male/female; BMI: body mass index; HR: heart rate; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.